{"entity":{"id":"emile-voest","kind":"person","name":"Emile Voest","aka":[],"tldr":"Led the DRUP trial giving off-label targeted drugs by genomic match, and developed organoid-based testing.","summary":"Emile Voest is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL). His specialisms are precision oncology, organoids and off-label drug access trials, and he works with patient-derived organoids, whole-genome sequencing and functional ex vivo drug testing. He founded the Dutch DRUP trial, which gives off-label targeted drugs by genomic match, and the Hartwig Medical Foundation whole-genome sequencing programme. His Nature paper on the Drug Rediscovery protocol described how this approach expands the use of existing anticancer drugs. He also developed patient-derived organoid co-cultures to test how tumours respond to immunotherapy. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Voest%20EE%5BAuthor%5D%20DRUP"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["organoids","wes-wgs","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute","institutionId":"nki","specialisms":["Precision oncology","Organoids","Off-label drug access trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Voest%20EE%5BAuthor%5D%20DRUP"}],"papers":[{"title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","journal":"Nature","year":2019,"doi":"10.1038/s41586-019-1600-x"},{"title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2400634","doi":"10.1056/NEJMoa2400634"}]},"route":"/people/emile-voest/","neighbours":{"technology":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"institution":[{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/"},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"paper":[{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/"}]}}